These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 29619980)

  • 21. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
    Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
    Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
    Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
    J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
    Mohamed E; Sierra RA; Trillo-Tinoco J; Cao Y; Innamarato P; Payne KK; de Mingo Pulido A; Mandula J; Zhang S; Thevenot P; Biswas S; Abdalla SK; Costich TL; Hänggi K; Anadon CM; Flores ER; Haura EB; Mehrotra S; Pilon-Thomas S; Ruffell B; Munn DH; Cubillos-Ruiz JR; Conejo-Garcia JR; Rodriguez PC
    Immunity; 2020 Apr; 52(4):668-682.e7. PubMed ID: 32294407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines.
    Wang Y; Zenkoh J; Gerelchuluun A; Sun L; Cai S; Li X; Tsuboi K
    Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):958-969. PubMed ID: 30458232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma.
    Orecchioni S; Talarico G; Labanca V; Calleri A; Mancuso P; Bertolini F
    Br J Cancer; 2018 May; 118(10):1329-1336. PubMed ID: 29695766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
    Sierra RA; Trillo-Tinoco J; Mohamed E; Yu L; Achyut BR; Arbab A; Bradford JW; Osborne BA; Miele L; Rodriguez PC
    Cancer Res; 2017 Oct; 77(20):5628-5638. PubMed ID: 28904063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.
    Boustani J; Lecoester B; Baude J; Latour C; Limagne E; Ladjohoulou R; Morgand V; Froidurot L; Ghiringhelli F; Truc G; Adotévi O; Mirjolet C
    Int J Radiat Biol; 2024; 100(6):912-921. PubMed ID: 38506658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.
    Ajona D; Ortiz-Espinosa S; Moreno H; Lozano T; Pajares MJ; Agorreta J; Bértolo C; Lasarte JJ; Vicent S; Hoehlig K; Vater A; Lecanda F; Montuenga LM; Pio R
    Cancer Discov; 2017 Jul; 7(7):694-703. PubMed ID: 28288993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
    Lin X; Zeng T; Xiong J; Zhang Q; Jiang P; Li X; Lin S; Xu Q; Weng H; Lai H; Gong H; Lin J; Cheng N; Tian X; Xu Y; Fang S; Jin R; Chen Z; Yang J; Morton L; Yueh B; Lin J
    Cancer Biol Ther; 2019; 20(5):666-679. PubMed ID: 30572778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization.
    Tan B; Shi X; Zhang J; Qin J; Zhang N; Ren H; Qian M; Siwko S; Carmon K; Liu Q; Han H; Du B; Liu M
    Cancer Res; 2018 Sep; 78(17):4929-4942. PubMed ID: 29967265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-Aminolevulinic acid/sodium ferrous citrate enhanced the antitumor effects of programmed cell death-ligand 1 blockade by regulation of exhausted T cell metabolism in a melanoma model.
    Hu X; Que W; Hirano H; Wang Z; Nozawa N; Ishii T; Ishizuka M; Ito H; Takahashi K; Nakajima M; Tanaka T; Zhu P; Guo WZ; Li XK
    Cancer Sci; 2021 Jul; 112(7):2652-2663. PubMed ID: 33934440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
    Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
    Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
    Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
    J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
    Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
    Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice.
    Hao H; Zhang Q; Zhu H; Wen Y; Qiu D; Xiong J; Fu X; Wu Y; Meng K; Li J
    Eur J Immunol; 2019 Dec; 49(12):2235-2244. PubMed ID: 31465113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasmodium infection inhibits the expansion and activation of MDSCs and Tregs in the tumor microenvironment in a murine Lewis lung cancer model.
    Adah D; Yang Y; Liu Q; Gadidasu K; Tao Z; Yu S; Dai L; Li X; Zhao S; Qin L; Qin L; Chen X
    Cell Commun Signal; 2019 Apr; 17(1):32. PubMed ID: 30979375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
    Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.